Full Press Release Details
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer.
IMMP
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Key Takeaway: Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Price reaction · baseline $2.3 (2023-05-23 close) · hit after-hours · 5 other IMMP headline(s) in the window, move may be shared
day 0 close
+6.5%
day 1
0%
day 3 · peak
-12.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)